The Middle East Tapentadol market, by Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, and Others), and Cough Treatment), and by Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) was valued at US$ 0.86 million in 2016 and is projected to exhibit a CAGR of 6.1% over the forecast period (2017–2025).
Rising prevalence of pain-associated diseases such as cancer and diabetic neuropathy and unavailability of effective alternate therapy for management of neuropathic pain are expected to be the major factors driving growth of the Middle East tapentadol market over the forecast period. Janssen Pharmaceutical sold its license of marketing and distribution of the U.S. to Depomed, Inc. and in April 2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical trials for tapentadol are being carried on for various indications and age groups.
Positive results from these trials is expected to cause the tapentadol market to gain rapid traction. Currently, tapentadol is only approved for consumption by adults and is not recommended for children due to its high therapeutic efficacy. However, one in three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label trial, enrolling subjects aged 6 years to 18 years, which is estimated to be completed in December 2018. Another trial by St. Olavs Hospital is for pre- and post-operative pain relief after primary knee arthroplasty with estimated study completion year 2021.
Browse 10 Market Data Tables And 11 Figures Spread Through 106 Pages and In-depth TOC on Middle East Tapentadol Market, By Therapeutic Application (Pain Management (Neuropathic Pain, Cancer Pain, And Others), And Cough Treatment), and By Countries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) - Forecast To 2025.
To know the latest trends and insights prevalent in the Middle East tapentadol market, click the link below:
https://www.coherentmarketinsights.com/market-insight/tapentadol-market-1054
Tapentadol can be used for various other applications, as it is also found to be the safest and best first-line treatment choice for advanced chronic kidney disease. However, clinical trials are still required for it to be prescribed for the same. Furthermore, pilot studies have been performed on patients suffering from moderate-to-severe chronic back pain, published in the National Center for Biotechnology Information. Increasing off-label applications for this moderately addictive drug along with low competition for existing indications, and robust pipeline is expected to boost growth of the tapentadol market over the forecast period.
Key Takeaways of the Middle East Tapentadol Market:
- The Middle East tapentadol market is expected to exhibit a CAGR of 1% over the forecast period (2017–2025), owing to the high prevalence of pain-related diseases in countries such as Iran, Palestine, and Kingdom of Saudi Arabia. For instance, according to Journal of Taibah University Medical Sciences, the prevalence of diabetic neuropathic pain in Iran was 51.90% in 2016.
- Positive results of clinical trials of tapentadol are expected to drive growth of the tapentadol market further
- Absence of generic drugs after patent win by Depomed, Inc. in 2016, has abolished the competition
- Less likelihood of tough competition from any other opioid for neuropathic pain and absence of any other opioid therapy under research is expected to support growth of the market
- Some major players operating in the tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan, Plc.
